Multiple tumor-associated antigens

Class

mRNA-lipid nanoparticle tumor-associated-antigen cancer vaccine

Pathway

MHC-mediated antigen presentation -> antigen-specific T-cell priming and tumor cell killing

Notes

original target text: Multiple tumor-associated antigens (TAAs; mRNA-lipid-nanoparticle-encoded, multi-antigen)

Tumor-associated antigens (TAAs) are proteins that cancer cells display in unusually high amounts, altered forms, or fetal-like patterns compared with normal tissue, making them candidate markers for the immune system to target. An mRNA-lipid nanoparticle (LNP) vaccine encoding multiple TAAs delivers synthetic messenger RNA, protected and carried into cells by a lipid shell, instructing host cells to manufacture the antigen proteins internally. These proteins are broken down and displayed on major histocompatibility complex (MHC) molecules at the cell surface, a process called antigen presentation, which activates and expands antigen-specific T cells capable of recognizing and killing tumor cells bearing the same markers. Encoding several antigens at once, rather than a single one, broadens the resulting immune response and helps counter tumor heterogeneity, since tumors can lose or downregulate any one antigen to evade detection, a phenomenon called antigen escape. This multi-antigen strategy is relevant across a range of solid and blood cancers where the goal is to mobilize the patient's own adaptive immune system, rather than relying solely on direct cytotoxic drugs, and it adapts vaccine technology originally developed for infectious pathogens to instead direct immunity against tumor-derived proteins.